Science 330 (6000), 8890
The SELECT study: a warning In 2023, semaglutide was shown to reduce the rates of major adverse cardiovascular events by 20% among persons with a history of atherosclerotic cardiovascular disease and obesity or in persons with overweight and one or more weight-related complications [79]
In an April post on X, Kennedy wrote that for each peptide, the committee will weigh the full clinical, pharmacological, and safety evidence. The next day, he asserted that these peptides are like supplements, and therefore might not need to go through clinical trials
GLP-1 Receptor Activation: When you eat, your body naturally releases GLP-1 to tell your brain you are full
Diabetes Complications 25, 244246
What Are the Benefits of Cagrilintide